Healthcare · Drug Manufacturers - Specialty & Generic

Emcure Pharmaceuticals Ltd.

EMCURE

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

NSE: EMCUREOfficial website ↗

Key metrics

Market Cap

₹30,344 cr

P/E Ratio

34.85x

P/B Ratio

6.82x

ROE

15.32%

ROCE

20.32%

Debt / Equity

0.23x

Net Margin

8.73%

Dividend Yield

19%

EPS

₹36.43

Period

FY2025

Shareholding pattern

As of Latest

Promoter: 81.74%FII: 5.15%Public: 13.11%

Deep-dive pages

10-Year Financials→Shareholding Pattern→Dividends & Corporate Actions→

Educational content — not investment adviceThis page presents publicly available information about Emcure Pharmaceuticals Ltd. for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing here constitutes investment advice, a recommendation to buy or sell any security, or a solicitation to transact. All financial data shown is sourced from public BSE/NSE filings and is at least 90 days old. Past performance is not indicative of future results. Please consult a SEBI-registered adviser before making any investment decision.